Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).This drug's approval has been highly contentious in the medical and scientific community owing to contradictory study findings and the FDA's advisory panel not recommending its approval.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000794244.40800.99 | DOI Listing |
Publication Analysis
Top Keywords
drug treat
8
treat alzheimer's
8
alzheimer's disease
8
controversial approval
4
approval drug
4
disease aducanumab
4
aducanumab aduhelm
4
aduhelm drug
4
disease 2003
4
2003 received
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!